Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birtamimab plus standard of care versus placebo plus standard of care in Mayo stage IV AL amyloidosis
NL-OMON54039Phase 3Recruiting
- Sponsor
- Prothena Corporation
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing Birtamimab plus standard of care, Placebo plus standard of care and Open-label extension birtamimab (3 arms). Primary endpoints: Time to all-cause mortality and Long-term safety. Started Jun 2022; status: recruiting.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NL-OMON54039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54039.